EC Digital Biotech
Biotech proved a surprisingly bright spot in 2022’s startup correction
While not totally immune to 2022's market correction, biotech fundraising proved to be more resilient than other sectors.
6 investors discuss why AI is more than just a buzzword in biotech
To get a better idea of how AI is affecting biotech in 2022, we asked six investors to tell us what they look for in a biotech startup today.
5 ways biotech startups can mitigate risk to grow sustainably in the long run
Capital is the fuel that advances scientific and technological innovation, but what do you do when the funding suddenly dries up?
Form Bio says now is the time to launch — despite cooling software sales
Form Bio was incubated within Colossal Biosciences and now is hoping to bring its workflow systems to other computational biology companies.
5 investors explain why longevity tech is a long-term play
It’s becoming clear that longevity as a theme has resonated with investors, though it appears it will be some time before more generalist investors take interest.
3 tips for biotech startups seeking non-dilutive capital to weather the downturn
In a downturn, non-dilutive grants or contracts from the government should be seen as more appealing than ever because they provide runway without dilution and make for great headlines.
For BioNTech, the COVID-19 vaccine was simply the opening act
Ultimately, BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place.
In an increasingly hot biotech market, protecting IP is key
Decisions about protecting your company’s IP can’t wait — founders must start aligning their IP and company strategies as soon as possible, even during the formation of the company itself.